Please wait while the formulary information is being retrieved.
NATPARA (PARATHYROID HORMONE)
- Hypocalcemia associated with hypoparathyroidism
100 mcg/dose subcutaneous cartridge
- Inject 100 mcg by subcutaneous route once daily in the thigh (alternating thighs with each dose)
25 mcg/dose subcutaneous cartridge
- Inject 25 mcg by subcutaneous route once daily in the thigh (alternating thighs with each dose)
50 mcg/dose subcutaneous cartridge
- Inject 50 mcg by subcutaneous route once daily in the thigh (alternating thighs with each dose)
75 mcg/dose subcutaneous cartridge
- Inject 75 mcg by subcutaneous route once daily in the thigh (alternating thighs with each dose)
Hypocalcemia associated with hypoparathyroidism
- Inject 25 mcg by subcutaneous route once daily in the thigh (alternating thighs with each dose)
- Inject 50 mcg by subcutaneous route once daily in the thigh (alternating thighs with each dose)
- Inject 75 mcg by subcutaneous route once daily in the thigh (alternating thighs with each dose)
- Inject 100 mcg by subcutaneous route once daily in the thigh (alternating thighs with each dose)
- None
Contraindicated
- None
Severe
Moderate
- None
- Osteosarcoma of bone
- Paget's disease of bone
- Radiation therapy involving bone
Contraindicated
- Hypercalcemia
Severe
Moderate
- Kidney disease with reduction in GFR
NATPARA (PARATHYROID HORMONE)
- Hypocalcemia associated with hypoparathyroidism
- Hypercalcemia
- Hypocalcemia
- Headache disorder
- Paresthesia
More Frequent
Severe
Less Severe
- Hypertension
- Arthralgias
- Diarrhea
- Hypercalcinuria
- Hypesthesia
- Nausea
- Neck pain
- Pain
- Sinusitis
- Upper abdominal pain
- Upper respiratory infection
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Dyspnea
- Seizure disorder
Less Severe
- Skin rash
- Urticaria
Contraindicated
None
Severe Precaution
Parathyroid Hormone
May be at increased risk of osteosarcoma. Avoid use in patient with open epiphyses. No safety and efficacy established.
- 1 Day – 18 Years
- May be at increased risk of osteosarcoma. Avoid use in patient with open epiphyses. No safety and efficacy established.
Management or Monitoring Precaution
None
Parathyroid Hormone
- Severity Level:
C
- Additional Notes: Insufficient human data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Parathyroid Hormone
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication has caused an increase in a type of bone cancer (osteosarcoma) in rats. It is unknown if it will increase the chance of bone cancer in humans. Before using this medication, tell your doctor or pharmacist your medical history, especially of Paget's disease or other bone disease, increase in a certain enzyme in your blood (alkaline phosphatase), personal/family history of bone cancer, or radiation treatment.<br /><br /> Talk with your doctor about the benefits and risks of using this medication. This medication should not be used by children and young adults whose bones are still growing, since they might have an increased risk of bone cancer. In the United States, all doctors, pharmacies, and patients must follow the requirements of the Natpara REMS Program to receive this medication. If you live in Canada or any other country, ask your doctor and pharmacist for your country's requirements.
| Hypocalcemia associated with hypoparathyroidism | |
| E20 | Hypoparathyroidism |
| E20.0 | Idiopathic hypoparathyroidism |
| E20.8 | Other hypoparathyroidism |
| E20.9 | Hypoparathyroidism, unspecified |
| E89.2 | Postprocedural hypoparathyroidism |
| 0-9 | A-Z |
|---|---|
| E20 | Hypoparathyroidism |
| E20.0 | Idiopathic hypoparathyroidism |
| E20.8 | Other hypoparathyroidism |
| E20.9 | Hypoparathyroidism, unspecified |
| E89.2 | Postprocedural hypoparathyroidism |
Formulary Reference Tool